Currently, three glycoengineered GBA enzymes (Imiglucerase, Velaglucerase alfa and Taliglucerase) with exposed mannose residues on N-glycans are used for treating non-neuropathic type I Gaucher disease. Here, GBA1 is linked to Gaucher disease.